Reimbursed Care Access in South Georgia and the South Sandwich Islands

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. In practice, SGSSI applies Commissioner-made ordinances and, where local law is silent, English/UK drug-control regimes (which place psilocybin/psilocin in the most restricted category, accessible only under Home Office licences for research). Any possession, supply or use outside a Home Office‑licenced research programme would be criminal. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. UK scheduling (applied in territories under Commissioner law where relevant) lists MDMA as a Class A / Schedule 1 equivalent offence for recreational possession and supply; lawful medical/research access requires Home Office licensing. # #.

Esketamine (marketed as Spravato) is a licensed medicine in the UK/EU for treatment‑resistant major depressive disorder under strict risk‑management and supervised administration conditions; it is regulated by UK medicines legislation and requires administration under direct healthcare supervision. The product is covered by UK regulatory approvals (Summary of Product Characteristics / SmPC maintained on the electronic medicines compendium) and by EMA/UK regulatory decisions; those approvals allow clinical use but they do not automatically create reimbursement or local availability in remote Overseas Territories. # #.

Regulatory / reimbursement implications for SGSSI: SGSSI has no NHS infrastructure or territory‑wide health‑insurance reimbursement programme; health services and law are administered by the Commissioner and statutory ordinances, and English law is applied to the extent practicable when local law is silent. Consequently, even though esketamine is MHRA/EMA‑approved in the UK/EU, routine reimbursement or organised local provision in SGSSI does not exist. Any access would require (a) import/administration authorised by the Commissioner and local medical officers; (b) compliance with UK controlled‑drug and medicines‑supply rules during import and administration; and (c) funding arranged privately (no local public reimbursement mechanism). # #.

Ketamine is a licit medicinal product under UK regulations when used for licensed indications (e.g., anaesthesia) and is commonly controlled as a Class B / Schedule 2 controlled drug for lawful medical use; it is also used off‑label in various jurisdictions for psychiatric indications but such off‑label usage requires an authorised prescriber and local clinical governance. UK regulatory material and guidance distinguish ketamine (used medically) from Schedule‑1 psychedelic research chemicals; ketamine can be prescribed/used in clinical settings but remains controlled. #.

In SGSSI any medical use of ketamine would be limited to authorised medical practice (e.g., anaesthesia for surgeries or emergency care provided under the Commissioner’s health arrangements) and would not be subject to local reimbursement: the territory lacks a public drug‑reimbursement programme, and supply or import would have to comply with Commissioner/ordnance importation controls and UK controlled‑drug rules. Off‑label psychiatric ketamine therapy therefore has no organised, reimbursed pathway in SGSSI and would require private funding and explicit approvals for importation/use. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Under UK scheduling (applied where relevant by SGSSI ordinances and English law application) DMT is in the most restricted schedule (Schedule 1 equivalent) and may only be obtained/used with a Home Office licence for research; there is no clinical‑care reimbursement or routine access in SGSSI. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. 5‑MeO‑DMT is treated like other tryptamine psychedelics under UK/Home Office controls; lawful use in SGSSI would require Home Office licences and Commissioner approval for import/administration in a research context. No reimbursement or routine clinical access exists. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Ibogaine is not an authorised medicine in UK frameworks and would require Home Office / research licencing to be lawfully possessed or used in SGSSI; there is no local clinical reimbursement. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Ayahuasca preparations typically contain DMT (a Schedule 1/Class A equivalent in UK law) and are therefore unlawful to possess/supply for human consumption in the territory except under a Home Office licence for research; no reimbursement or regulated therapeutic access exists in SGSSI. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline (and mescaline extracts) are controlled under UK classification (Class A/Schedule 1 equivalent for many plant‑derived extracts), meaning possession/supply for human consumption is unlawful in SGSSI unless specifically licenced for research; there is no local reimbursement pathway. Note: certain legal technicalities exist in UK law regarding whole‑plant peyote vs extract formulations, but those are handled by UK/Home Office scheduling and would apply in SGSSI where English law is applied. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. 2C‑series substituted phenethylamines (commonly referred to as “2C‑X”) are controlled under UK drug legislation (usually via generic/temporary classing and specific scheduling additions) and therefore are unlawful in SGSSI except within licenced research; no reimbursement or therapeutic access exists. # #.